Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer

Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer

Objectives: To evaluate the impact of bowel resection at the time of interval cytoreductive surgery on survival. Methods: We identified patients with advanced ovarian cancer who underwent neoadjuvant chemotherapy and interval cytoreductive surgery between 2008 and 2018 from a single-institution tumo...

Full description

Bibliographic Details
Main Authors:	Blair McNamara, Rosa Guerra, Jennifer Qin, Amaranta D. Craig, Lee-may Chen, Madhulika G. Varma, Jocelyn S. Chapman
Format:	Article
Language:	English
Published:	Elsevier 2021-11-01
Series:	Gynecologic Oncology Reports
Subjects:	Bowel resection Ovarian cancer Neoadjuvant chemotherapy Interval cytoreduction
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352578921001740

Similar Items

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study
by: Ester Miralpeix, et al.
Published: (2022-02-01)

Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery
by: Kevin W McCool, et al.
Published: (2018-10-01)

The role of cytoreduction surgery in advanced ovarian cancer (review)
by: R K Tandelov, et al.
Published: (2018-03-01)

Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction
by: Pratistha Koirala, et al.
Published: (2020-08-01)

The outcomes of isolated ureteral resection and reconstruction in non-urologic cancer patients who underwent cytoreductive surgery (CRC) and hyperthermic intraperitoneal chemotherapy (HIPEC)
by: Şevket Barış Morkavuk, et al.
Published: (2019-12-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer
by: Claudèle Brault, et al.
Published: (2023-12-01)

A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction
by: Francois Kraus, et al.
Published: (2021-09-01)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
by: Angeliki Andrikopoulou, et al.
Published: (2023-07-01)

A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
by: Mitchell Clark, et al.
Published: (2021-11-01)

Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations
by: Nathaniel Deboever, et al.
Published: (2023-08-01)

Does MIS Play a Role in the Treatment of Advanced Ovarian Cancer?
by: Augusto Pereira, et al.
Published: (2022-07-01)

Colorectal cancer with synchronous distant metastases: rationale for cytoreductive surgery and its perspectives – a surgeons view
by: V. A. Aliyev, et al.
Published: (2015-02-01)

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
by: Soo Young Jeong, et al.
Published: (2019-12-01)

Primary versus interval debulking surgery in the management of ovarian cancer patients, current data summary
by: Victoria Psomiadou, et al.
Published: (2022-04-01)

Quaternary and beyond cytoreduction: An updated and expanded analysis
by: Beryl L. Manning-Geist, et al.
Published: (2021-08-01)

A case of pancreaticoduodenectomy and partial hepatic resection as repeat cytoreductive surgery for recurrent pseudomyxoma peritonei
by: Kenya Yamanaka, et al.
Published: (2021-12-01)

Gynae-Oncology Surgeons’ Preparedness to Undertake Colorectal Procedures during Cytoreductive Surgery for Ovarian Cancer: A Cross Sectional Survey
by: Daniel Huddart, et al.
Published: (2022-10-01)

Postoperative pulmonary complications and outcomes in cytoreductive surgery for ovarian cancer: a propensity-matched analysis
by: Mengmeng Xu, et al.
Published: (2022-04-01)

Current Status and Controversies in Neoadjuvant Chemotherapy for Advanced Stage Ovarian Cancer: A Review
by: Jiaxi Li, et al.
Published: (2023-11-01)

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
by: Eleonora Ghisoni, et al.
Published: (2018-05-01)

Quality of life of patients with bowel endometriosis before and after laparoscopic bowel resection
by: Aleksandra Vujanović, et al.
Published: (2017-02-01)

Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
by: Caixia Jiang, et al.
Published: (2021-09-01)

Neoadjuvant chemotherapy does not improve survival for patients with high volume colorectal peritoneal metastases undergoing cytoreductive surgery
by: Mina Sarofim, et al.
Published: (2024-04-01)

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review
by: Chen Vicky, et al.
Published: (2022-11-01)

Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study
by: Semiramis L. Carbajal-Mamani, et al.
Published: (2020-03-01)

Parcelar gastric resection in association with bowel resections as part of debulking surgery for advanced stage ovarian cancer – a case report
by: Nicolae Bacalbasa, et al.
Published: (2021-06-01)

Synchronous liver and peritoneal metastases from colorectal cancer: Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection a feasible option?
by: Sara Di Carlo, et al.
Published: (2022-12-01)

Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients
by: Anna Weiss, et al.
Published: (2018-04-01)

Relationship Between Neoadjuvant Chemotherapy and Log Odds of Positive Lymph Nodes and Their Prognostic Role in Advanced Ovarian Cancer Patients With Optimal Cytoreductive Surgery
by: Yue-min Hou, et al.
Published: (2022-05-01)

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes
by: Daniele Marrelli, et al.
Published: (2022-12-01)

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)
by: Koen P. Rovers, et al.
Published: (2019-04-01)

CYTOREDUCTIVE OPERATIONS IN TREATMENT OF THE PATIENTS OF ELDERLY AND SENILE AGE WITH DISSEMINATED FORMS OF COLORECTAL CANCER
by: N. A. Maistrenko, et al.
Published: (2016-04-01)

Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study
by: Hyunji Lim, et al.
Published: (2022-06-01)

Hepatic Hilar Lymph Node Resection in Cytoreductive Surgery for Advanced Ovarian Cancer: A Necessity or Not?
by: Huang H, et al.
Published: (2021-10-01)

The impact of neoadjuvant chemotherapy on low anterior resection syndrome after rectal cancer resection: A 6 Months longitudinal follow-up
by: Qiulu Zhang, et al.
Published: (2021-10-01)

Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction
by: Mackenzie Cummings, et al.
Published: (2022-04-01)

Long Term Survival after Cytoreductive Surgery Combined with Perioperative Chemotherapy in Gastric Cancer Patients with Peritoneal Metastasis
by: Yutaka Yonemura, et al.
Published: (2020-01-01)

How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated—A Comprehensive Review
by: Daria Kwaśniewska, et al.
Published: (2023-08-01)